Tunlametinib

Catalog No.E1943 Batch:E194301

Print

Technical Data

Formula

C16H12F2IN3O3S

Molecular Weight 491.25 CAS No. 1801756-06-8
Solubility (25°C)* In vitro DMSO 98 mg/mL (199.49 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Tunlametinib (HL-085) is a highly selective and oral inhibitor of MEK1/2 with an IC50 of 1.9 nM for MEK1, with the potential to treat RAS/RAF mutant cancers. It also induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in a dose-dependent manner. It also exhibits antitumor activity in patients with advanced NRAS-mutant melanoma.

Protocol (from reference)

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.